MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,372,426 | -21.2% | 4,145,643 | +6.4% | 0.00% | 0.0% |
| Q2 2023 | $42,329,783 | +443.7% | 3,897,770 | +245.4% | 0.00% | – |
| Q1 2023 | $7,786,049 | +81.5% | 1,128,413 | +4.7% | 0.00% | – |
| Q4 2022 | $4,290,242 | -32.7% | 1,077,950 | +12.4% | 0.00% | – |
| Q3 2022 | $6,379,000 | +40.0% | 959,198 | +1.9% | 0.00% | – |
| Q2 2022 | $4,556,000 | -81.4% | 941,311 | -64.2% | 0.00% | -100.0% |
| Q1 2022 | $24,553,000 | -31.5% | 2,626,028 | -13.0% | 0.00% | 0.0% |
| Q4 2021 | $35,841,000 | +5.1% | 3,016,889 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $34,107,000 | -36.9% | 2,997,203 | -0.6% | 0.00% | -50.0% |
| Q2 2021 | $54,090,000 | +28.2% | 3,015,028 | +10.6% | 0.00% | +100.0% |
| Q1 2021 | $42,207,000 | +66.3% | 2,726,638 | +31.1% | 0.00% | 0.0% |
| Q4 2020 | $25,378,000 | +12.7% | 2,080,091 | +18.7% | 0.00% | 0.0% |
| Q3 2020 | $22,520,000 | – | 1,752,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |